Oncolytic adenoviruses for the treatment of brain tumors

Area of Science:

• Oncolytic virotherapy
• Cancer biology
• Molecular oncology

Background:

• Oncolytic viruses, specifically adenoviruses, are engineered for selective cancer cell targeting and are in clinical trials.
• Adenovirus infection induces autophagy, offering new insights into adenovirus-mediated cell death mechanisms.
• Genetic engineering of adenoviruses allows for modulation of protein expression and tissue selectivity.

Purpose of the Study:

• To review the role of autophagy in oncolytic adenovirus replication and cell death.
• To explore strategies for enhancing oncolytic virus selectivity using microRNA (miRNA) targeting.
• To discuss the rationale for combining oncolytic adenoviruses with chemotherapy for cancer treatment.

Main Methods:

• Review of current literature on oncolytic adenoviruses, autophagy, and miRNA targeting.
• Analysis of studies investigating adenovirus-induced autophagy and its enhancement by inducers like rapamycin.
• Examination of methods for engineering miRNA-specific adenoviruses for tumor selectivity.
• Assessment of studies on adenovirus-mediated inhibition of MGMT and chemosensitization of glioma cells.

Main Results:

• Adenovirus replication induces autophagy, which can be modulated to enhance oncolytic effects.
• MicroRNA (miRNA)-targeted sequences can be engineered into adenoviruses to achieve tissue- and tumor-specific targeting.
• Adenoviruses can inhibit MGMT expression, sensitizing glioma cells to temozolomide chemotherapy.

Conclusions:

• Oncolytic adenoviruses offer a promising platform for cancer therapy through mechanisms including autophagy induction and targeted gene modulation.
• Exploiting miRNA specificity presents a viable strategy for developing safer and more effective tissue- and tumor-selective oncolytic viruses.
• Combination therapy with oncolytic adenoviruses and chemotherapeutic agents, such as temozolomide, demonstrates synergistic potential in cancer treatment.